Publication Name	World Journal of Stem Cells
Manuscript ID	63308
Country	Türkiye

Received	2021-01-27 09:00
Peer-Review Started	2021-01-27 09:05
First Decision by Editorial Office Director	2021-02-28 05:40
Return for Revision	2021-02-28 05:40
Revised	2021-04-02 12:18
Publication Fee Transferred
Second Decision by Editor	2021-06-16 13:22
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2021-06-16 13:55
Articles in Press	2021-06-16 13:55
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-06-23 10:52
Publish the Manuscript Online	2021-06-26 07:48

ISSN	1948-0210 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, Research & Experimental
Manuscript Type	Review
Article Title	Genome engineering and disease modeling via programmable nucleases for insulin gene therapy; promises of CRISPR/Cas9 technology
Manuscript Source	Invited Manuscript
All Author List	Yunus E Eksi, Ahter D Sanlioglu, Bahar Akkaya, Bilge Esin Ozturk and Salih Sanlioglu
Funding Agency and Grant Number	Funding Agency Grant Number the Akdeniz University Scientific Research Commission and the Scientific and Technological Research Council of Turkey TUBITAK-215S820
Corresponding Author	Salih Sanlioglu, DVM, PhD, Chairman, Professor, Department of Gene and Cell Therapy, Akdeniz University Faculty of Medicine, Dumlupınar Boulevard, Campus, Antalya 07058, Türkiye. ssanlioglu@icloud.com
Key Words	Programmable nucleases; CRISPR/Cas9; Stem cells; Disease modeling; Diabetes; Insulin gene therapy
Core Tip	In this review, CRISPR/Cas9 nuclease is deployed in the generation of cellular and animal models of diabetes, which are suitable for the testing of the treatment efficacy of novel insulin gene therapy approaches.
Publish Date	2021-06-26 07:48
Citation	Eksi YE, Sanlioglu AD, Akkaya B, Ozturk BE, Sanlioglu S. Genome engineering and disease modeling via programmable nucleases for insulin gene therapy; promises of CRISPR/Cas9 technology. World J Stem Cells 2021; 13(6): 485-502
URL	https://www.wjgnet.com/1948-0210/full/v13/i6/485.htm
DOI	https://dx.doi.org/10.4252/wjsc.v13.i6.485

Full Article (PDF)	WJSC-13-485.pdf
Full Article (Word)	WJSC-13-485.docx
Manuscript File	63308_Auto_Edited-ZMG.doc
Answering Reviewers	63308-Answering reviewers.pdf
Audio Core Tip	63308-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	63308-Conflict-of-interest statement.pdf
Copyright License Agreement	63308-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	63308-Language certificate.pdf
Peer-review Report	63308-Peer-review(s).pdf
Scientific Misconduct Check	63308-Bing-Ma YJ-1.jpg
Scientific Misconduct Check	63308-Bing-Liu M-2.png
Scientific Misconduct Check	63308-Scientific misconduct check.pdf
Scientific Editor Work List	63308-Scientific editor work list.pdf
CrossCheck Report	63308-CrossCheck report.pdf